# Plerixafor

Source: https://onco.cc/drugs/plerixafor/  
OnCo record `plerixafor` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Plerixafor (Mozobil) is an injection given with G-CSF to flush stem cells out of the bone marrow into the blood so that enough can be collected for an autologous transplant in myeloma or lymphoma.

## Summary

Plerixafor was approved by the FDA in December 2008 in combination with filgrastim to mobilise haematopoietic stem cells for collection and autologous transplantation in non-Hodgkin lymphoma and multiple myeloma, on two placebo-controlled phase 3 trials in which the proportion of patients reaching the target cell dose in few apheresis sessions roughly doubled; the EU authorised Mozobil in 2009 and a paediatric extension followed. It is used routinely for poor mobilisers and increasingly pre-emptively, and the same CXCR4 blockade underlies its investigation to mobilise stem cells for gene therapy and to sensitise leukaemia to chemotherapy. Motixafortide (Aphexda, 2023) is a longer-acting CXCR4 antagonist for the same purpose. Diarrhoea, nausea and injection-site reactions are common.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Also known as: AMD3100
- Tags: nci-list; supportive
- Brand: Mozobil
- Modality: Small-molecule CXCR4 antagonist (stem cell mobiliser)
- Mechanism: Bicyclam that reversibly blocks CXCR4 binding of stromal-derived factor-1 (CXCL12), releasing haematopoietic stem cells from bone marrow niches into the blood within hours.
- Approvals: US 2008: Stem cell mobilisation with filgrastim for autologous transplantation in NHL and multiple myeloma; EU 2009: Stem cell mobilisation with G-CSF in lymphoma and multiple myeloma with poor mobilisation (Mozobil)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Plerixafor
- US label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=plerixafor
- NCI drug page: https://www.cancer.gov/about-cancer/treatment/drugs/plerixafor
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil

## Connected records

- drugs: [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Motixafortide](https://onco.cc/drugs/motixafortide/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Apheresis and starting-material collection](https://onco.cc/technologies/apheresis-starting-material/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/)
- targets: [CXCR4](https://onco.cc/targets/cxcr4/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)
- trials: [Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation](https://onco.cc/trials/nct01767714/), [Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide](https://onco.cc/trials/nct01301963/), [Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients](https://onco.cc/trials/nct00103662/)

---
JSON: https://onco.cc/api/v1/entities/plerixafor.json